TWI873210B - 用於治療患有ｈｅｒ２及ｈｅｒ３陽性癌症之對象的手段及方法 - Google Patents

用於治療患有ｈｅｒ２及ｈｅｒ３陽性癌症之對象的手段及方法 Download PDF

Info

Publication number
TWI873210B
TWI873210B TW109136884A TW109136884A TWI873210B TW I873210 B TWI873210 B TW I873210B TW 109136884 A TW109136884 A TW 109136884A TW 109136884 A TW109136884 A TW 109136884A TW I873210 B TWI873210 B TW I873210B
Authority
TW
Taiwan
Prior art keywords
erbb
cancer
sequence
gene
nrg1
Prior art date
Application number
TW109136884A
Other languages
English (en)
Chinese (zh)
Other versions
TW202130664A (zh
Inventor
恩尼斯托 Ｉ 瓦瑟曼
黎翁納德 Ａ 西魯尼克
Original Assignee
荷蘭商美勒斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷蘭商美勒斯公司 filed Critical 荷蘭商美勒斯公司
Publication of TW202130664A publication Critical patent/TW202130664A/zh
Application granted granted Critical
Publication of TWI873210B publication Critical patent/TWI873210B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109136884A 2019-10-24 2020-10-23 用於治療患有ｈｅｒ２及ｈｅｒ３陽性癌症之對象的手段及方法 TWI873210B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2024097 2019-10-24
NL2024097 2019-10-24

Publications (2)

Publication Number Publication Date
TW202130664A TW202130664A (zh) 2021-08-16
TWI873210B true TWI873210B (zh) 2025-02-21

Family

ID=68807359

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109136884A TWI873210B (zh) 2019-10-24 2020-10-23 用於治療患有ｈｅｒ２及ｈｅｒ３陽性癌症之對象的手段及方法

Country Status (9)

Country Link
US (1) US20220372166A1 (enExample)
EP (1) EP4048702A1 (enExample)
JP (2) JP7532514B2 (enExample)
KR (1) KR20220103954A (enExample)
CN (2) CN114761436A (enExample)
AU (1) AU2020371040B2 (enExample)
CA (1) CA3158609A1 (enExample)
TW (1) TWI873210B (enExample)
WO (1) WO2021080428A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058341A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828043A1 (en) * 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6967853B2 (ja) * 2014-02-28 2021-11-17 メルス ナムローゼ フェンノートシャップ ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
WO2015130172A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
US20210206875A1 (en) * 2017-03-31 2021-07-08 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
BR112019024230A2 (pt) * 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
JP2023548375A (ja) * 2020-11-04 2023-11-16 メルス ナムローゼ フェンノートシャップ Ｅｒｂｂ３変異陽性がんを有する対象を治療するための手段及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Magdalena Malm, et al., Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds", mAbs, Vol.8, Issue 7, 無, 08 September 2016, Pages 1195–1209 *
網路文獻 Merus N.V., "Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor", 無, 2019/09/20, https://www.clinicaltrials.gov/study/NCT04100694?intr=MCLA-128&rank=2&tab=history&a=1; *

Also Published As

Publication number Publication date
US20220372166A1 (en) 2022-11-24
WO2021080428A1 (en) 2021-04-29
EP4048702A1 (en) 2022-08-31
KR20220103954A (ko) 2022-07-25
AU2020371040B2 (en) 2025-10-09
JP7532514B2 (ja) 2024-08-13
JP2024071393A (ja) 2024-05-24
CA3158609A1 (en) 2021-04-29
CN114761436A (zh) 2022-07-15
TW202130664A (zh) 2021-08-16
AU2020371040A1 (en) 2022-05-12
JP2022553104A (ja) 2022-12-21
CN116327919A (zh) 2023-06-27
JP7678175B2 (ja) 2025-05-15

Similar Documents

Publication Publication Date Title
US12247078B2 (en) ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
KR20160092992A (ko) 암 바이오마커 및 이의 용도
US20240026029A1 (en) Means and methods for treating subjects with erbb3 mutation positive cancer
JP7678175B2 (ja) Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
CN118055949A (zh) 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
KR102905513B1 (ko) NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
WO2025188180A1 (en) Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
WO2025245489A1 (en) Treatment of tumors in subjects having fgl-1 positive samples
CN120882752A (zh) 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法
CN120435311A (zh) 用pd-1轴结合拮抗剂和rna疫苗治疗胰腺癌的方法
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene